BioCardia targets Japanese approval for heart failure therapy by 2027
BioCardia provided a regulatory update outlining near-term milestones for its CardiAMP and Helix programs. BioCardia is working toward a Shonin pre-market submission to Japan’s Pharmaceutical and Medical Device Agency in Q4 2026 and has supplied detailed responses to PMDA consultation questions whil
<p>BioCardia provided a regulatory update outlining near-term milestones for its CardiAMP and Helix programs. BioCardia is working toward a Shonin pre-market submission to Japan’s Pharmaceutical and Medical Device Agency in Q4 2026 and has supplied detailed responses to PMDA consultation questions whil</p>